Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne

Summary

The purpose of the trial is to evaluate the safety, efficacy and immunogenicity of up to 3 intramuscular injections of the Acne mRNA vaccine candidate at up to four dose levels in adult participants aged 18 to 45 years with moderate to severe acne. This trial will consist of a Core Study followed by an optional Long-Term Extension (LTE). The Core Study will consist of: Two cohorts evaluating the 2-administration regimen (Cohorts A): Sentinel Cohort A and Main Cohort A. Two cohorts evaluating the 3-administration regimen (Cohorts B): Sentinel Cohort B and Main Cohort B.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Acne

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1/2

Ages

18 to 45 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Sanofi Pasteur, a Sanofi Company

Last updated on ClinicalTrials.gov

August 21, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites